Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Tesamorelin (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 07 Nov 2012 Status changed from active, no longer recruiting to completed.
- 26 Sep 2012 Results published in the Journal of Clinical Endocrinology and Metabolism.
- 27 Jun 2012 Primary endpoint 'Visceral-adipose tissue' has been met.